Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

Exclusion Criteria

• •1. Acute promyelocytic leukemia
• •2. Acute leukemia of ambiguous lineage (biphenotypic leukemia)
• •3. Active signs or symptoms of CNS involvement by malignancy
• •4. No prior G-CSF, GM-CSF or plerixafor within 14 days of study drug dosing
• •5. Known history or evidence of active hepatitis A, B, or C or HIV
• •6. Uncontrolled acute life threatening bacterial, viral or fungal infection
• •7. Active graft versus host disease (GVHD) ≥ Grade 2 or extensive chronic GVHD requiring immunosuppressive therapy
• •8. Hematopoietic stem cell transplantation ≤ 4 months of dosing
• •9. Clinically significant cardiovascular disease